Biologics in polymyositis and dermatomyositis-associated interstitial lung disease.
Curr Pharm Biotechnol
; 15(6): 521-4, 2014.
Article
en En
| MEDLINE
| ID: mdl-25213360
Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Productos Biológicos
/
Polimiositis
/
Enfermedades Pulmonares Intersticiales
/
Dermatomiositis
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Pharm Biotechnol
Asunto de la revista:
BIOTECNOLOGIA
/
FARMACOLOGIA
Año:
2014
Tipo del documento:
Article